Provectus Biopharmaceuticals, Inc.
PVCT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.20 | 1.00 | 0.27 | 0.20 |
| FCF Yield | -6.51% | -6.39% | -6.70% | -4.51% |
| EV / EBITDA | -11.78 | -14.95 | -14.16 | -5.09 |
| Quality | ||||
| ROIC | 141.75% | 63.20% | 85.71% | 194.86% |
| Gross Margin | 98.84% | -204.77% | 93.55% | 0.00% |
| Cash Conversion Ratio | 0.69 | 0.83 | 0.86 | 0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | -14.55% | – | – | – |
| Free Cash Flow Growth | -27.69% | 15.44% | -200.15% | 75.20% |
| Safety | ||||
| Net Debt / EBITDA | -0.64 | -1.02 | -0.66 | -0.23 |
| Interest Coverage | -16.54 | -13.42 | -20.94 | -4.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -56,440.90 | -359.72 | -11,985.24 | -4,992.64 |